The US Food and Drug Administration (FDA) APPROVED mepolizumab (Nucala) for use in combination with other medications for maintenance treatment of severe asthma in patients aged 12 years or older and with an eosinophilic phenotype.
Mepolizumab is not approved for use in patients with other eosinophilic conditions or for emergency treatment of acute bronchospasm or status asthmaticus.
This treatment is only indicated for those with Severe Asthma whose main trigger is eosinophilic inflammation. This is a subcutaneous injectable given into the thigh or arm once every 4 weeks and relieves severe asthma attacks by lowering levels of serum eosinophils (an allergic cell in the blood that triggers Asthma).
The FDA article discussing its approval of Nucala can be found here
Press release from GlaxoSmithKline announcing the FDA approval of Nucala can be found here
